Ranked among the best health establishments by Le Point, the IUCT-Oncopole of Toulouse confirms its benchmark status in oncology. A ranking that the Toulouse clinic owes in particular to its remarkable performances in numerous specialties.
The 2024 ranking of the best hospitals and clinics in France published by Le Point on December 5 once again highlights the excellence of French health establishments. Like the Toulouse University Hospital, the University Cancer Institute of Toulouse Oncopole (IUCT-Oncopole) has been able to shine and rank among the best clinics according to specialties. This establishment, dedicated to cancer care, research and training, has established itself as a key player in health in France.
The IUCT-Oncopole classified in certain disciplines
While “the Toulouse University Hospital is classified in almost all specialties”, the IUCT-Oncopole stands out perfectly in several areas. Here are his remarkable performances in the national rankings:
- 2e for uterine cancers.
- 3e for ENT and breast cancers.
- 4e for ovarian cancer and adult leukemia.
- 6e for thyroid cancers as well as lymphomas and myelomas.
- 7e for surgery of soft tissue sarcomas and skin cancers.
This broad spectrum of recognized specialties illustrates the collective dynamic and commitment of the 2,000 professionals who work on the site.
Professor Jean-Pierre Delord, Director General of IUCT-Oncopole, is proud of these results: “We are very well ranked in each of our specialties, which testifies to the collective dynamic at work on the IUCT-Oncopole site. ‘Oncopolis. I would like to congratulate all the staff for their efforts and commitment. » At the same time, the Toulouse University Hospital, with which IUCT-Oncopole is associated, takes first place in the general table of French hospitals.
The Toulouse clinic has become a reference
The IUCT-Oncopole is a unique site in France, combining cutting-edge clinical care, innovative research and continuing education. Labeled Comprehensive Cancer Center, it treats more than 11,000 new patients each yearone in eight of which participates in clinical trials. This alliance between innovation and personalized care is reinforced by partnerships with public and private actors, including manufacturers.
Furthermore, the IUCT-Oncopole continues its development in a framework that combines precision medicine, advanced technologies and translational research. This distinction in the national ranking not only marks recognition of what already exists, but also a promise for patients and for future advances in oncology.
